Literature DB >> 7545683

Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20.

J P Deans1, L Kalt, J A Ledbetter, G L Schieven, J B Bolen, P Johnson.   

Abstract

CD20, a non-glycosylated cell-surface protein expressed exclusively on B lymphocytes, is one of a family of 4-pass transmembrane molecules that also includes the beta chain of the high affinity receptor for IgE. The precise function of CD20 is unknown, although in vitro effects of CD20-specific antibodies on resting B cells indicate that it is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. Previous studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases. Here, analysis of CD20-associated molecules has revealed that CD20 is associated with the Src family tyrosine kinases p56/53lyn, p56lck, and p59fyn and with 75/80-kDa proteins phosphorylated in vivo on tyrosine residues. Mutagenesis of CD20 was performed to define regions of CD20 involved in intermolecular interactions. Mutants were analyzed in the human T lymphoblastoid cell line Molt-4, in which ectopically expressed wild-type CD20 associated with p59fyn, p56lck, and 75/80-kDa phosphoproteins. Deletion of major portions of the cytoplasmic regions of CD20 did not abolish its association with either p75/80 or tyrosine kinases. The interaction between CD20 and the Src-related kinases is therefore likely to be independent of CD20 cytoplasmic domains and may occur indirectly. The interaction may be mediated by the p75/80 phosphoproteins, which were found to be tightly associated with the Src family kinases isolated from the CD20 complex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545683     DOI: 10.1074/jbc.270.38.22632

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

Review 1.  CD20-mediated apoptosis: signalling through lipid rafts.

Authors:  Julie P Deans; Haidong Li; Maria J Polyak
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

Review 2.  What signals are generated by anti-CD20 antibody therapy?

Authors:  Benjamin Bonavida
Journal:  Curr Hematol Malig Rep       Date:  2006-12       Impact factor: 3.952

Review 3.  The MS4A family: counting past 1, 2 and 3.

Authors:  Li Eon Kuek; Melanie Leffler; Graham A Mackay; Mark D Hulett
Journal:  Immunol Cell Biol       Date:  2015-04-03       Impact factor: 5.126

4.  Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.

Authors:  E Janas; R Priest; J I Wilde; J H White; R Malhotra
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

5.  Patterns of expression, membrane localization, and effects of ectopic expression suggest a function for MS4a4B, a CD20 homolog in Th1 T cells.

Authors:  Hui Xu; Mark S Williams; Lisa M Spain
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

6.  An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.

Authors:  Isabel Vogler; Sebastian Newrzela; Sylvia Hartmann; Nadine Schneider; Dorothee von Laer; Ulrike Koehl; Manuel Grez
Journal:  Mol Ther       Date:  2010-05-11       Impact factor: 11.454

7.  Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.

Authors:  Ping-Chiao Tsai; Francisco J Hernandez-Ilizaliturri; Naveen Bangia; Scott H Olejniczak; Myron S Czuczman
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

8.  Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.

Authors:  Rui Zhang; Jiyuan Yang; Te-Wei Chu; Jonathan M Hartley; Jindřich Kopeček
Journal:  Adv Healthc Mater       Date:  2015-01-21       Impact factor: 9.933

9.  Rituximab sensitizes a Burkitt lymphoma cell line to cell killing by X-irradiation.

Authors:  Min Fengling; Liu Fenju; Wen Wanxin; Zhai Lijia; Tong Jiandong; Wang Zu; Yuan Xin; Gao Qingxiang
Journal:  Radiat Environ Biophys       Date:  2009-08-04       Impact factor: 1.925

Review 10.  Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Hagop M Kantarjian
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.